Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

napabucasin 3Irinotecan 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2Paclitaxel 2Leucovorin 2Fluorouracil 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Oncolytic Virotherapy 1Ocoxin 1Nivolumab 1Leuprolide 1Interferon-gamma 1Immunotherapy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gefitinib 1Filgrastim 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Glandular and Epithelial × Nivolumab × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡